Omega Therapeutics Inc (OMGA) - News Archive

Showing 4 of 4 results.

Omega Therapeutics Unveils Breakthrough Epigenomic Medicine OTX-2002 in Nature Communications,

Omega Therapeutics Announces Landmark Publication of Preclinical OTX-2002 Data in Nature Communications CAMBRIDGE, Mass. Sept. 17, 2024 Omega Therapeutics, Inc. (Nasdaq: OMGA), a leading clinical-stage biotechnology fir...

Sep 17, 2024 • Biotechnology & Pharmaceuticals Industry Clinical Study

Omega Therapeutics Appoints Dr. Jennifer Nelson as Senior Vice President of Research, Bolstering Epigenomic Medicine Innovations,

Omega Therapeutics Appoints Jennifer Nelson, Ph.D., as Senior Vice President of ResearchCAMBRIDGE, Mass., Aug. 14, 2024 – Omega Therapeutics, a leading biotechnology company focused on the development of programmable ep...

Aug 14, 2024 • Biotechnology & Pharmaceuticals Industry Management Changes

Omega Therapeutics Unveils New Preclinical Data, Showcases Promising Epigenomic Controllers in Functional Gene Expression Upregulation

Encouraging Outcomes from the Ground-breaking Epigenomic Alteration ResearchOmega Therapeutics is a clinical-stage biotech outfit who has made its defining essence by leveraging the body s epigenomic control mechanisms...

May 8, 2024 • Biotechnology & Pharmaceuticals Industry Product Service News

Omega Therapeutics Presents Promising Findings on Epigenomic Control at AACR 2024, Paving the Way for Innovative Cancer Treatments

Reprogramming Cancer: Omega Therapeutics Unveils Promising Preclinical Data at AACR 2024CAMBRIDGE, Mass., April 09, 2024 Omega Therapeutics, a groundbreaking clinical-stage biotechnology company specializing in programm...

Apr 9, 2024 • Biotechnology & Pharmaceuticals Industry Clinical Study